HOME FDD
    
     
  Formula Design and Development (FDD) Section

FDD Logo

The Formulation Design & Development Section is comprised of members from many diverse backgrounds in industry, regulatory and academia who share a common interest in the area of formulation design, research and development - a multidisciplinary field drawing upon the physical, chemical, biological and engineering sciences. The primary goal of this section is to unite multiple scientific disciplines in a forum where they can share experimental results, consider new formulation and dosage form technologies, and discuss issues and concerns regarding the design and development of formulations/drug products for all dosage forms. This Section collaboratively interfaces with other sections which focus on pre-formulation, biopharmaceutics, formulation strategies, and manufacturing process optimization.

Aspects of formulation design and development include the study of dosage forms for drug delivery via all routes of administration wherein the dosage form encompasses the formulation, process by which it is made, and primary packaging. The Section’s focus on development includes product design, delivery systems and technology, stability, quality, and performance both in vitro and in vivo that is appropriate to its development stage.

Section Vision

The Formulation Design and Development Section will be the premier worldwide forum for scientists dedicated to the design and development of all dosage forms.

Section Mission

The Formulation Design and Development Section provides a dynamic international forum for the exchange of formulation-related knowledge among scientists to enhance their contributions to health. We offer timely formulation-related scientific programs, on-going education, opportunities for networking, and professional development by:

  • Providing forums for the free interchange and dissemination of scientific knowledge, particularly in the area of formulation design and development;
  • Fostering the scientific and technical growth of scientists in the discipline;
  • Promoting and recognizing excellence in the discipline;
  • Encouraging the support of basic academic, industrial, and regulatory research programs and the development of mutually beneficial relationships;
  • Encouraging students to enter the discipline by strengthening and increasing the viability of academic programs in formulation design and development;
  • Collaborating with and supporting other AAPS sections, focus groups, and other professional/scientific organizations; and
  • Informing the public of major advances in formulation design and development.

Newsletter Section Connection

FDD Section Bylaws


Formulation Design and Development Headlines

Findings Confirm H1N1 Flu's Toll on Pregnant Women
Reuters Health Information Services (02/26/10)

Teasing Vaccines From Tobacco
Wall Street Journal (02/24/10) P. A6; Naik, Gautam

EU Panel Says Becaplermin Must Not Be Used in Cancer Patients
Dow Jones Newswires (02/18/10) Ball, Elliot

Fridge-Free Vaccine Hopes Raised
BBC News (02/18/10) Dreaper, Jane

Complimentary AAPS E-Learning Module To Discuss Liposomal and Nanoparticle Agents
AAPS Press Release (02/23/2010)

One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study
USP (02/08/2010)

FDA Approves Collagenase Clostridium Histolyticum (Xiaflex) for Treatment of Dupuytren's Contracture
FDA.gov (02/02/10)

Performance of Equipment to Test Dissolution of Medications Further Assured
USP (02/09/2010)

The European Medicine Agency Road Map to 2015: The Agency's Contribution to Science, Medicines, Health
European Medicines Agency (01/26/2010)

UCF-Developed Vaccine May Fight Malaria, Cholera
Orlando Business Journal (01/26/10)

Immune Response Better With Skin Scratch Vaccination
Business Week (01/18/10)

New Sensor Could Help Treat, Combat Diabetes, Other Diseases
ScienceDaily (01/21/10)

AAPS to Host 45th Annual Pharmaceutical Technologies Arden Conference
AAPS Press Release (01/26/2010)

Insulin Pumps Might Have Slight Advantage in Type 1 Diabetes
Newswise (01/15/10)

Diabetes Insight Could Lead to Better Treatments
Business Week (12/21/09) Gardner, Amanda

Orphan Drug Workshops Scheduled for Feb. 25-26 and Aug. 3-4
FDA.gov (12/23/09)

Researchers Get $9.85 Million for Malaria Vaccine
Philadelphia Inquirer (12/18/09) Kanaley, Reid

Light Shed on Genetic Variation
Financial Times (12/18/09) Milton, Joseph

 


Chair
Colin M. Minchom, Ph.D.
Patheon Inc.
Mississauga, ON Canada


Chair-Elect
Dave Wallick, Ph.D.
The Dow Chemical Company
Midland, MI UNITED STATES


Vice Chair
Samantha Lai, Ph.D.
Tamlylin
Mountain View, CA United States


Secretary/Treasurer
Lori R. Hilden, Ph.D.
Eli Lilly & Company
Indianapolis, IN


Past Chair
Mansoor A. Khan, R.Ph., Ph.D.
FDA/CDER/DPQR, HFD-941
Silver Spring, MD UNITED STATES


Member at Large
David Y. Mitchell, Ph.D.
Mitchell Pharmaceutical Consulting, LLC
Lafayette, CO United States


Click here for a list of the entire FDD Section leadership

.
American Association of Pharmaceutical Scientists
2107 Wilson Blvd, Suite 700, Arlington, VA 22201-3042
Main Telephone: 703 243 2800 Main Fax: 703 243 9650
Email: aaps@aaps.org
View disclaimer
View Privacy Statement
Please email your comments or questions regarding this web site to
webmaster@aaps.org